CorMedix Inc (CRMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CorMedix Inc (CRMD) has a cash flow conversion efficiency ratio of 0.233x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($94.46 Million) by net assets ($405.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CorMedix Inc market capitalisation for the company's overall valuation and market capitalisation.
CorMedix Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how CorMedix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CorMedix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CorMedix Inc ranked by their cash flow conversion efficiency. Explore how high is CorMedix Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huatian Hotel Group Co Ltd
SHE:000428
|
0.016x |
|
Luyan Pharma Co Ltd
SHE:002788
|
0.035x |
|
Guangdong Xiongsu Technology Group Co Ltd
SHE:300599
|
0.001x |
|
OppFi Inc
NYSE:OPFI
|
0.265x |
|
Wuxi Xinhongtai ElecTech
SHG:603016
|
0.034x |
|
Jiangsu Flowers King
SHG:603007
|
-0.022x |
|
Seche Environnem.
PA:SCHP
|
0.100x |
|
Bichamp Cutting Technology Hunan Co Ltd
SHE:002843
|
-0.025x |
Annual Cash Flow Conversion Efficiency for CorMedix Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of CorMedix Inc from 2008 to 2025. View CorMedix Inc (CRMD) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $405.31 Million | $175.05 Million | 0.432x | +172.24% |
| 2024-12-31 | $84.66 Million | $-50.61 Million | -0.598x | -9.18% |
| 2023-12-31 | $70.14 Million | $-38.41 Million | -0.548x | -23.79% |
| 2022-12-31 | $55.06 Million | $-24.36 Million | -0.442x | -31.31% |
| 2021-12-31 | $62.80 Million | $-21.16 Million | -0.337x | +32.18% |
| 2020-12-31 | $44.22 Million | $-21.97 Million | -0.497x | +21.96% |
| 2019-12-31 | $23.65 Million | $-15.05 Million | -0.637x | +86.75% |
| 2018-12-31 | $4.93 Million | $-23.70 Million | -4.803x | -20.86% |
| 2017-12-31 | $7.19 Million | $-28.59 Million | -3.974x | -217.97% |
| 2016-12-31 | $17.81 Million | $-22.27 Million | -1.250x | -239.34% |
| 2015-12-31 | $34.01 Million | $-12.53 Million | -0.368x | +78.82% |
| 2014-12-31 | $3.63 Million | $-6.32 Million | -1.739x | -293.32% |
| 2013-12-31 | $-4.02 Million | $-3.62 Million | 0.900x | -81.21% |
| 2012-12-31 | $-475.38K | $-2.28 Million | 4.788x | +194.03% |
| 2011-12-31 | $1.24 Million | $-6.30 Million | -5.092x | -907.15% |
| 2010-12-31 | $7.26 Million | $-3.67 Million | -0.506x | -446.48% |
| 2009-12-31 | $-14.71 Million | $-2.15 Million | 0.146x | -57.32% |
| 2008-12-31 | $-12.03 Million | $-4.11 Million | 0.342x | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Pi… Read more